The American Journal of Surgery
Volume 199, Issue 2 , Pages 189-198 , February 2010

ATA practice guidelines for the treatment of differentiated thyroid cancer: were they followed in the United States?

  • Olatokunbo M. Famakinwa, B.A.

      Affiliations

    • Department of Surgery, Yale University School of Medicine, New Haven, CT, USA
    • ,
  • Sanziana A. Roman, M.D.

      Affiliations

    • Department of Surgery, Yale University School of Medicine, New Haven, CT, USA
    • Corresponding Author InformationCorresponding author. Tel.: 203-785-2563; fax: 203-785-4067
    • ,
  • Tracy S. Wang, M.D., M.P.H.

      Affiliations

    • Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA
    • ,
  • Julie Ann Sosa, M.A., M.D.

      Affiliations

    • Department of Surgery, Yale University School of Medicine, New Haven, CT, USA

Received 2 March 2009 ,Revised 29 April 2009

References 

  1. Grubbs EG, Rich TA, Li G, et al. Recent advances in thyroid cancer. Curr Probl Surg. 2008;45:156–250
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  3. Elaraj DM, Clark OH. Changing management in patients with papillary thyroid cancer. Curr Treat Options Oncol. 2007;8:305–313
  4. Shaha A. Treatment of thyroid cancer based on risk groups. J Surg Oncol. 2006;94:683–691
  5. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94:692–700
  6. Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin N Am. 2007;36:807–822
  7. Sywak M, Cornford L, Roach P, et al. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery. 2006;140:1000–1007
  8. White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg. 2007;31:895–904
  9. Low TH, Delbridge L, Sidhu S, et al. Lymph node status influences follow-up thyroglobulin levels in papillary thyroid cancer. Ann Surg Oncol. 2008;15:2827–2832
  10. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–142
  11. AACE/AAES Medical/Surgical Guidelines for Clinical Practice: Management of Thyroid Carcinoma. Endocr Pract. 2001;7:202–220
  12. Pacini F, Schlumberger M, Dralle H, et al. European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803
  13. British Thyroid Association, Royal College of Physicians. Guidelines for the management of thyroid cancer. In: Report of the Thyroid Cancer Guidelines Update Group. 2nd ed.. London: Royal College of Physicians; 2007;
  14. American Head and Neck Society. Practice guidelines: thyroid. http://www.headandneckcancer.org/clinicalresources/docs/diffthyroid.phpAccessed July 25, 2008
  15. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed October 10, 2008
  16. Gharib H, Papini E, Pashcke R. Thyroid nodules: a review of current guidelines, practices, and prospects. Eur J Endocrinol. 2008;159:493–505
  17. Vidal-Trecan GM, Pazart LH, Massol JA. A method for guideline development: assessing practical feasibility and adaptation of thyroid nodule guidelines. J Eval Clin Pract. 1999;5:189–198
  18. Hundahl SA, Cady B, Cunningham MP, et al. ; US and German Thyroid Cancer Study Group (Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996). Cancer. 2000;89:202–217
  19. Van den Bruel A, Moreno-Reyes R, Bex M, et al. Is the management of thyroid nodules and differentiated thyroid cancer in accordance with recent consensus guidelines? (Results of a national survey). Clin Endocrinol. 2008;68:599–604
  20. Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005, National Cancer Institute. http://seer.cancer.gov/csr/1975_2005/
  21. AJCC cancer staging manual. In: 5th ed.. Philadelphia: Lippincott-Raven; 1997;
  22. Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000;
  23. Studnicki J, Schapira DV, Bradham DD, et al. Response to the National Cancer Institute Alert (The effect of practice guidelines on two hospitals in the same medical community). Cancer. 1993;72:2986–2992
  24. Mullan F. Wrestling with variation: an interview with Jack Wennberg. Health Aff (Millwood) Suppl Web Excl. 2004;VAR73–80
  25. Lazovich D, Solomon CC, Thomas DB, et al. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer. 1999;86:628–637
  26. White J, Morrow M, Moughan J, et al. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer. 2003;97:893–904
  27. Sosa JA, Mehta PJ, Wang TS, et al. Racial disparities in clinical and economic outcomes from thyroidectomy. Ann Surg. 2007;246:1083–1091
  28. Sosa JA, Mehta PJ, Wang TS, et al. A population-based study of outcomes from thyroidectomy in aging Americans: at what cost?. J Am Coll Surg. 2008;206:1097–1105
  29. Mahadevia PJ, Sosa JA, Levine MA, et al. Clinical management of primary hyperparathyroidism and thresholds for surgical referral: a national study examining concordance between practice patterns and consensus panel recommendations. Endocr Pract. 2003;9:494–503
  30. Sosa JA, Powe NR, Levine MA, et al. Thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons. J Clin Endocrinol Metab. 1998;83:2658–2665
  31. Kouvouraki MA, Greer M, Sharma S, et al. Indications for operative intervention in patients with asymptomatic primary hyperparathyroidism: practice patterns of endocrine surgery. Surgery. 2006;139:527–534
  32. Bennedbaek FN, Hegedüs L. Management of the solitary thyroid nodule: results of a North American study. J Clin Endocrinol Metab. 2000;85:2493–2498
  33. Bonnema SJ, Bennedbaek FN, Wiersinga WM, et al. Management of the nontoxic multinodular goiter: a European questionnaire study. Clin Endocrinol. 2000;53:5–12
  34. Bennedbaek FN, Perrild H, Hegedüs L. Diagnosis and treatment of the solitary thyroid nodule (Results of a European survey). Clin Endocrinol. 2001;50:357–363
  35. Bonnema SJ, Bennedbaek FN, Ladenson PW, et al. Management of the nontoxic multinodular goiter: a North American survey. J Clin Endocrinol Metab. 2002;87:112–117
  36. Walsh JP, Ryan SA, Lisewski D, et al. Differences between endocrinologists and endocrine surgeons in management of the solitary thyroid nodule. Clin Endocrinol. 2007;66:844–853
  37. Doherty GM. Invited commentary: routine central neck lymph node dissection for thyroid carcinoma. Surgery. 2006;140:1007–1008
  38. Henry JF, Gramatica L, Denizot A, et al. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg. 1998;383:167–169
  39. National Cancer Institute. SEER: Surveillance, Epidemiology, and End Results Program. http://www.seer.cancer.gov/about/SEER_brochure.pdfAccessed September 21, 2009

PII: S0002-9610(09)00529-7

doi: 10.1016/j.amjsurg.2009.04.022

The American Journal of Surgery
Volume 199, Issue 2 , Pages 189-198 , February 2010

Article Tools